Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 265

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 265
---
    325 |   |     |      |      - |   |
| Net cash provided by financing activities                                   |     |                    |    325 |   |     |      |      - |   |
| Net change in cash and cash equivalents                                     |     |                    |   (895 | ) |     |      | (1,504 | ) |
| Cash and cash equivalents at the beginning of the period                    |     |                    |  1,240 |   |     |      |  2,744 |   |
| Cash and cash equivalents at the end of the year                            |     | $                  |    345 |   |     | $    |  1,240 |   |
| Non-cash financing activities:                                              |     |                    |        |   |     |      |        |   |
| 2021 Notes conversion into preferred D-2 shares                             |     | $                  |  1,086 |   |     | $    |      - |   |

<div align='center'>The accompanying notes are an integral part of
the financial statements.

F-21</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 1:- | GENERAL |

| a. | Regentis Biomaterials Ltd. (the “Company”) commenced operations in September 2004. The Company develops innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients. The Company’s current efforts are focused on orthopedic treatments using our Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue. Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen. The Company’s lead product candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. |

| b. | Transaction with OceanTech Corp. |

On May 2, 2023, OceanTech Acquisitions
I Corp., a Delaware corporation (“OceanTech”), R.B. Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of OceanTech
(“Merger Sub”), Aspire Acquisition LLC, OceanTech’s sponsor (the “Sponsor”), and the Company executed a
definitive Agreement and Plan of Mer